Abstract
High-mobility group box 1 (HMGB1) has been implicated in a variety of biologically important processes, including transcription, DNA repair, V(D)J recombination, differentiation, development, and extracellular signaling. The increased expression of HMGB1 has been described in colorectal cancer (CRC). However, there is no report about the correlation of HMGB1 with clinicopathologic features, including the survival of patients with CRC. In present study, we investigated HMGB1 expression and its prognostic significance in CRC by performing immunohistochemical analysis, using a total of 192 paraffin-embedded archival CRC samples. Moreover, disruption of endogenous HMGB1 protein through a siRNA knockdown technique was performed to investigate the possible role of HMGB1 in the process of tumor invasion and metastasis. Overexpression of HMGB1 was shown in 55.7% cases. Statistical analysis showed that HMGB1 expression was positively correlated with tumor invasion (P = 0.048), lymph node metastasis (P = 0.011), distant metastasis (P = 0.031), and Duke's stage (P = 0.029) of CRC patients. Patients with higher HMGB1 expression had shorter overall survival time, whereas patients with lower level of HMGB1 had better survival. Multivariate analysis suggested that HMGB1 expression might be an independent prognostic indicator for the survival of patients with CRC. Disruption of endogenous HMGB1 protein through a siRNA knockdown technique was shown to suppress substantially the invasion ability of SW620 cells. Our results suggest that HMGB1 protein is a valuable marker for progression of CRC patients. High HMGB1 expression is associated with poor overall survival in patients with CRC.
MeSH Terms
Adult
Aged
Aged, 80 and over
Biomarkers, Tumor/analysis
Cell Line, Tumor
Cell Movement
Colorectal Neoplasms/metabolism,mortality,pathology
Disease Progression
Female
HMGB1 Protein/genetics,metabolism
Humans
Male
Middle Aged
Prognosis
Survival Analysis
Chemicals
Biomarkers, Tumor
HMGB1 Protein
Authors & Affiliations
6 authors, click to expand affiliations / ORCID
Yao Xingjun
Department of Surgery, The First Affiliated Hospital of Jilin University, Changchun, People's Republic of China.
Zhao Gang
Yang Hongfa
Hong Xinyu
Bie Li
Liu Guojin
References (22)
22 references, click to expand
-
Extracellular HMGB1, a signal of tissue damage, induces mesoangioblast migration and proliferation.
J Cell Biol. 2004 Feb 2;164(3):441-9
PMID: 14744997
-
Differential effects between amphoterin and advanced glycation end products on colon cancer cells.
Int J Cancer. 2003 May 10;104(6):722-7
PMID: 12640679
-
Serum high mobility group box-1 (HMGB1) is closely associated with the clinical and pathologic features of gastric cancer.
J Transl Med. 2009 May 28;7:38
PMID: 19476625
-
Cyclooxygenase-2 expression correlates with tumor neovascularization and prognosis in human colorectal carcinoma patients.
Clin Cancer Res. 2000 Oct;6(10):4064-8
PMID: 11051257
-
High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal.
Nat Rev Immunol. 2005 Apr;5(4):331-42
PMID: 15803152
-
Receptor for advanced glycation end products (RAGE) and its ligand, amphoterin are overexpressed and associated with prostate cancer development.
Prostate. 2005 Jun 15;64(1):92-100
PMID: 15666359
-
Rapid increase in colorectal cancer rates in urban Shanghai, 1972-97, in relation to dietary changes.
J Cancer Epidemiol Prev. 2002;7(3):143-6
PMID: 12665213
-
Biology of human colon cancer metastasis.
World J Surg. 1995 Mar-Apr;19(2):226-34
PMID: 7754628
-
Cancer statistics, 2006.
CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30
PMID: 16514137
-
Increased expression of high mobility group box 1 (HMGB1) is associated with an elevated level of the antiapoptotic c-IAP2 protein in human colon carcinomas.
Gut. 2006 Feb;55(2):234-42
PMID: 16118352
-
Overexpression of high mobility group (HMG) B1 and B2 proteins directly correlates with the progression of squamous cell carcinoma in skin.
Cancer Invest. 2008 Oct;26(8):843-51
PMID: 18798064
-
Receptor for advanced glycation end products (RAGE)-mediated neurite outgrowth and activation of NF-kappaB require the cytoplasmic domain of the receptor but different downstream signaling pathways.
J Biol Chem. 1999 Jul 9;274(28):19919-24
PMID: 10391939
-
Co-expression of receptor for advanced glycation end products and the ligand amphoterin associates closely with metastasis of colorectal cancer.
Oncol Rep. 2003 Mar-Apr;10(2):445-8
PMID: 12579287
-
Global gene expression profiles of human head and neck squamous carcinoma cell lines.
Int J Cancer. 2004 Nov 1;112(2):249-58
PMID: 15352037
-
HMG-1 as a late mediator of endotoxin lethality in mice.
Science. 1999 Jul 9;285(5425):248-51
PMID: 10398600
-
Non-Hodgkin lymphoma expressing high levels of the danger-signalling protein HMGB1.
Leuk Lymphoma. 2008 Jun;49(6):1184-9
PMID: 18569640
-
Cyclooxygenase-2 expression: a significant prognostic indicator for patients with colorectal cancer.
Clin Cancer Res. 2004 Dec 15;10(24):8465-71
PMID: 15623626
-
Increased expression of high mobility group box 1 (HMGB1) is associated with progression and poor prognosis in human nasopharyngeal carcinoma.
J Pathol. 2008 Oct;216(2):167-75
PMID: 18680137
-
Release of chromatin protein HMGB1 by necrotic cells triggers inflammation.
Nature. 2002 Jul 11;418(6894):191-5
PMID: 12110890
-
Intracellular high mobility group B1 protein (HMGB1) represses HIV-1 LTR-directed transcription in a promoter- and cell-specific manner.
Virology. 2003 Sep 15;314(1):179-89
PMID: 14517071
-
Overexpression of high mobility group box 1 in gastrointestinal stromal tumors with KIT mutation.
Cancer Res. 2003 May 1;63(9):2188-93
PMID: 12727838
-
Dual roles for HMGB1: DNA binding and cytokine.
J Endotoxin Res. 2001;7(4):315-21
PMID: 11717586